Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > HTA Debates in 2018-2019
HTA Debates in 2018-2019
-
Japan to Roll Out Cost-Effectiveness Assessment Scheme in April
February 21, 2019
-
Importance of Non-ICER Factors in Cost-Effectiveness Assessment Starting to Resonate with Chuikyo Reps
February 7, 2019
-
Tough CEA Rules for Cost-Based Method Products Targeting Imports: EFPIA Japan Vice Chair
February 7, 2019
-
Japan, US, European Trade Groups Give Opinions on Govt’s CEA Proposal: Chuikyo
February 7, 2019
-
PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework
February 5, 2019
-
MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo
January 24, 2019
-
CEFP Finalizes Govt Reform Timeline Urging FY2019 Debate on “Economic Evaluations” for Reimbursement Decisions
December 21, 2018
-
Chuikyo Snubs Industry’s Call to Exclude Listed Products from CEA Scope
December 20, 2018
-
PhRMA, EFPIA Pitch Enhanced Appraisal Model for Japan HTA Plan; Chuikyo Reps Acknowledge ICER Limitations
December 20, 2018
-
Govt’s Draft Reform Timeline Prods MHLW to Discuss Use of “Economic Evaluations” in Reimbursement Decisions in FY2019
December 11, 2018
-
National Institute of Public Health to Play Core Role in CEA Public Analysis Process
December 6, 2018
-
Chuikyo Agrees on 3 ICER Thresholds for “Tiered” CEA Price Adjustment Model; Industry Hearing Slated by Year-End
December 6, 2018
-
MHLW Eyes Drastic Change to Cost Effective Analysis Flow, Enhanced Discussions Upfront
November 22, 2018
-
MHLW Proposes Quarterly Product Selections, Price Tweaks for CEA Scheme: Chuikyo
November 22, 2018
-
MOF Panel Urges Govt to Use Economic Evaluations for Reimbursement Decisions: FY2019 Budget Recommendation
November 21, 2018
-
Health Economist Calls for Robust Appraisal Process in Japan CEA System
November 20, 2018
-
Experts Say ICER Deduction Unscientific, MHLW Proposes Different Thresholds for Cancer and Orphan Drugs
November 8, 2018
-
Chuikyo Supports Price Raise Rules for Cost-Effective Products
November 8, 2018
-
MHLW Pitches “Tiered Model” for CEA Price Tweak, but Faces Chuikyo Opposition
November 8, 2018
-
Limit CEA Application to Premium-Given Drugs with Big Sales: EFPIA Japan Officials
October 29, 2018
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…